Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY), a biomedical company dedicated to women's reproductive health, will attend the 78th Annual ASRM Scientific Congress in Anaheim, California, from October 22-26, 2022. The management team will showcase innovative technologies such as FemaSeed® and FemVue® at booth #1011. Femasys aims to address women's needs globally with minimally invasive in-office products, including FemBloc® for permanent birth control and FemCath™ for assessing fallopian tubes. To learn more, visit www.femasys.com.

ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company’s management team will be attending the 78^th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress to be held in Anaheim, California from October 22-26, 2022.

Members of the management team will be showcasing its technologies, including FemaSeed^® and FemVue^®, at its booth #1011.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, and FemCerv^®, an endocervical tissue sampler are currently being marketed in the United States. Femasys is also advancing FemCath^™, an intrauterine catheter for selective evaluation of the fallopian tubes intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com 

Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com 

Femasys Inc.
Investor Contact:
IR@femasys.com 

Media Contact:
Media@femasys.com 

FAQ

What is Femasys showcasing at the ASRM Scientific Congress?

Femasys is showcasing its technologies, including FemaSeed® and FemVue®, at the ASRM Scientific Congress.

When is the ASRM Scientific Congress where Femasys will participate?

The ASRM Scientific Congress will be held from October 22-26, 2022.

Where is the ASRM Scientific Congress taking place?

The ASRM Scientific Congress is taking place in Anaheim, California.

What are Femasys's lead product candidates?

Femasys's lead product candidates include FemBloc® for permanent birth control and FemaSeed® for localized directional insemination.

What technologies has Femasys developed for reproductive health?

Femasys has developed technologies such as FemVue® for fallopian tube assessment and FemCath™ for selective evaluation of the fallopian tubes.